"Tumor cell dormancy is a major root for glioblastoma relapse," said Dr. Zou. "Our team of vascular biologists, bioengineers, and neuroscientists are employing a 3D vascular glioblastoma organoid model to understand governing factors in the tumor microenvironment that promote tumor stem cell dormancy, therapy resistance, and tumor re-propagating capacity."
• Defining the Chromatin Landscape and Transcriptional Drivers of Proliferation and Migration in Human Glioblastoma
Ad Statistics
Times Displayed: 111887
Times Visited: 6707 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
• Crosstalk between EGFR and TEAD Activity Directs Migration in Human Glioblastoma
A better understanding of the mechanisms by which glioblastoma cells infiltrate deep into the brain, evading surgical resection and chemotherapy, is needed in order to prevent tumor progression. Nadejda Tsankova, MD, PhD, Associate Professor of Pathology, and Neuroscience, at the Icahn School of Medicine at Mount Sinai, is the Principal Investigator on two studies that examine the biology of migration in glioblastoma cells. The first NIH-funded study aims to define the epigenetic landscape (nongenetic influences on gene expression) and transcriptional networks that drive properties of growth and migration in human glioblastoma cells. The second study focuses on the role of one specific transcription factor, the transcriptional enhanced associate domain (TEAD) as driver of the migratory tumor cell state, and explores its relationship to epidermal growth factor receptor (EGFR) signaling, using CRISPR-knockout and pharmacological inhibition in primary patient-derived glioblastoma cells and in immunocompetent and xenograft mouse glioma models. Dr. Tsankova has received nearly $275,000 for the first study and more than $1.8 million in funding for the second, five-year study.
"We have uncovered TEAD1 as an important driver of tumor migration," said Dr. Tsankova. "Through our studies, we aim to gain deeper mechanistic insight into the biology of tumor migration as well as to test the therapeutic efficacy of pharmacological inhibitors of TEAD1 activity in pre-clinical mouse glioma models."
• Molecular and cellular mechanisms of glioma invasion
Roland H. Friedel, PhD, Associate Professor of Neuroscience, and Neurosurgery, at the Icahn School of Medicine at Mount Sinai, is the Principal Investigator of an NIH-funded project ($1.8 million for a five-year period) to study signaling pathways that promote the migratory potential of glioblastoma invasion.
